Hubei Hongyuan Pharmaceutical Technology Co (SZSE:301246) EPS (Basic): ¥0.64 (TTM As of Mar. 2026)


SZSE:301246 Hubei Hongyuan Pharmaceutical Technology Co Ltd SZSE:301246
75 GF Score
Price ¥26.46
GF Value ¥19.02
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Hubei Hongyuan Pharmaceutical Technology Co EPS (Basic)?

Hubei Hongyuan Pharmaceutical Technology Co SZSE:301246 -6.44% 75 EPS (Basic) is ¥0.64 as of Mar. 2026. GuruFocus rates SZSE:301246 with a GF Score™ of 75/100 and a GF Value™ of ¥19.02 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Hubei Hongyuan Pharmaceutical Technology Co's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was ¥0.36. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.64.

Hubei Hongyuan Pharmaceutical Technology Co's EPS (Diluted) for the three months ended in Mar. 2026 was ¥0.36. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.64.

Hubei Hongyuan Pharmaceutical Technology Co's EPS without NRI for the three months ended in Mar. 2026 was ¥0.38. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 0.72.

During the past 12 months, Hubei Hongyuan Pharmaceutical Technology Co's average EPS without NRIGrowth Rate was 389.80% per year. During the past 3 years, the average EPS without NRI Growth Rate was -41.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was -44.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was -3.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Hubei Hongyuan Pharmaceutical Technology Co's highest 3-Year average EPS without NRI Growth Rate was 99.60% per year. The lowest was -74.80% per year. And the median was -8.50% per year.

Hubei Hongyuan Pharmaceutical Technology Co  (SZSE:301246) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Hubei Hongyuan Pharmaceutical Technology Co EPS (Basic) Related Terms

Hubei Hongyuan Pharmaceutical Technology Co EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Hubei Hongyuan Pharmaceutical Technology Co's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hubei Hongyuan Pharmaceutical Technology Co EPS (Basic) Chart

Hubei Hongyuan Pharmaceutical Technology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.40 1.23 0.23 0.13 0.30

Hubei Hongyuan Pharmaceutical Technology Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 -0.04 0.01 0.30 0.36
SZSE:301246
75GF Score
Hubei Hongyuan Pharmaceutical Technology Co Ltd SZSE:301246
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hubei Hongyuan Pharmaceutical Technology Co EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Hubei Hongyuan Pharmaceutical Technology Co's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(119.053-0)/396.977
=0.30

Hubei Hongyuan Pharmaceutical Technology Co's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(144.348-0)/396.777
=0.36

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ¥0.64 mean?
Hubei Hongyuan Pharmaceutical Technology Co (SZSE:301246) has a EPS (Basic) of ¥0.64 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Hubei Hongyuan Pharmaceutical Technology Co and its competitors.
Is Hubei Hongyuan Pharmaceutical Technology Co's EPS (Basic) too high?
Hubei Hongyuan Pharmaceutical Technology Co's current EPS (Basic) is ¥0.64. Overall, Hubei Hongyuan Pharmaceutical Technology Co has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hubei Hongyuan Pharmaceutical Technology Co's EPS (Basic) compare to ZTS?
Hubei Hongyuan Pharmaceutical Technology Co's EPS (Basic) of ¥0.64 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Hubei Hongyuan Pharmaceutical Technology Co and its competitors. Hubei Hongyuan Pharmaceutical Technology Co's current EPS (Basic) is ¥0.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hubei Hongyuan Pharmaceutical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Hubei Hongyuan Pharmaceutical Technology Co (SZSE:301246) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥19.02, compared to a current price of ¥26.46 — trading 39.1% above its estimated fair value. The current EPS (Basic) is ¥0.64. Hubei Hongyuan Pharmaceutical Technology Co's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Hubei Hongyuan Pharmaceutical Technology Co (SZSE:301246), the current EPS (Basic) is ¥0.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hubei Hongyuan Pharmaceutical Technology Co (SZSE:301246) Overvalued in 2026?

Based on GuruFocus' analysis, Hubei Hongyuan Pharmaceutical Technology Co stock appears to be overvalued. The current stock price of ¥26.46 is trading 39.1% above its estimated GF Value™ of ¥19.02. GuruFocus considers Hubei Hongyuan Pharmaceutical Technology Co to be Significantly Overvalued.

Key valuation signals for SZSE:301246:

  • EPS (Basic): ¥0.64
  • GF Value™: ¥19.02 vs. price of ¥26.46 (39.1% above fair value)
  • GF Score™: 75/100 with 7 warning signs

No single metric tells the full story. See the SZSE:301246 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hubei Hongyuan Pharmaceutical Technology Co Business Description

Address No. 8, Hongyuan Road, Economic Development Zone, Luotian County, Hubei Province, Fengshan Town, CHN, 438600
Hubei Hongyuan Pharmaceutical Technology Co Ltd is engaged in the research and development, production and sales of organic chemical raw materials, pharmaceutical intermediates, raw materials and pharmaceutical preparations.
75GF Score

Get the complete analysis for SZSE:301246

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥26.46
Price
¥19.02
GF Value